Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
0.75 ^USD	+0.32%		+0.01%	-33.04%

20/05	Bolt Biotherapeutics, Inc. Announces Management Changes	CI
20/05	Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	CI

Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes

May 20, 2024 at 10:52 pm IST

Bolt Biotherapeutics, Inc. announced that Randall C. Schatzman, Ph.D. stepped down as the Company?s Chief Executive Officer, effective as of May 15, 2024. Effective May 15, 2024, William P. Quinn, the Company's Chief Financial Officer since 2020, also became the Chief Executive Officer. Mr. Quinn will continue to serve as the Company?s Chief Financial Officer.

Latest news about Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. Announces Management Changes	20/05	CI
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	20/05	CI
Top Midday Decliners	15/05	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05	MT
Top Premarket Decliners	15/05	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05	MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	15/05	MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05	MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05	MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	15/05	MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03	CI
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu	05/12	CI
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing	01/12	MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/23/23	CI
Bolt Biotherapeutics Begins Dosing in Advanced Cancers Phase 1/2 Study of BDC-3042	17/23/17	MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	29/23/29	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	28/23/28	MT
Bolt Biotherapeutics Says US FDA Granted Orphan Drug Designation for BDC-1001 for Gastric Cancer	28/23/28	MT
Bolt Biotherapeutics Says Candidate Cancer Treatment Secures Patent	12/23/12	MT
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	12/23/12	MT

Chart Bolt Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bolt Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.75 USD

Average target price

1.25 USD

Spread / Average Target

+66.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BOLT BIOTHERAPEUTICS, INC.	-33.04%	2.86Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.6TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.59TCr
BEIGENE, LTD.	-20.90%	1.51TCr
WUXI APPTEC CO., LTD.	-46.14%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.39TCr

Bio Therapeutic Drugs